Hexarelin Molecular Structure & Chemical Properties

Hexarelin, also known by its International Nonproprietary Name examorelin, represents one of the most potent synthetic growth hormone secretagogues in the GHRP family. Developed in the 1990s by Europeptides and Mediolanum Farmaceutici, this hexapeptide has generated substantial research interest due to its robust growth hormone-releasing properties and unique cardiovascular effects that distinguish it from other GHRPs. Unlike its predecessor GHRP-6, hexarelin exhibits greater chemical stability through the substitution of tryptophan with 2-methyl-D-tryptophan, providing enhanced resistance to enzymatic degradation and a longer duration of action. With over three decades of preclinical investigation, hexarelin has become a valuable research tool for understanding growth hormone regulation, cardiac protection mechanisms, and metabolic pathways.

Chemical Structure

2D molecular structure (Source: PubChem)

Technical Specifications

The peptide’s structure features D-amino acid substitutions at positions 2 and 5, which confer greater stability compared to naturally occurring L-amino acids. The 2-methyl group on the D-tryptophan residue at position 2 provides enhanced metabolic stability while maintaining high receptor binding affinity.

Hexarelin Mechanism of Action

Hexarelin exerts its biological effects primarily through activation of the growth hormone secretagogue receptor (GHSR-1a), a G-protein-coupled receptor originally identified in the hypothalamus and pituitary gland. However, research has revealed that hexarelin’s actions extend well beyond simple growth hormone release, involving multiple receptor systems and signaling pathways that contribute to its diverse physiological effects. This multi-receptor profile distinguishes hexarelin from other GHRPs and accounts for its unique cardiovascular and metabolic activities.

Primary Cellular Pathways

GHSR-1a Activation – Growth Hormone Release

Hexarelin binds to and activates GHSR-1a receptors located in both the hypothalamus and anterior pituitary gland, triggering a cascade that results in pulsatile growth hormone secretion. Research demonstrates that hexarelin stimulates growth hormone release more potently than growth hormone-releasing hormone (GHRH) itself in many experimental models. Key findings include:

• Dose-dependent GH release with peak plasma concentrations occurring 30 minutes post-administration in human studies
• Synergistic effects when combined with GHRH, producing massive increases in plasma growth hormone levels
• Reduced somatostatin activity, indirectly enhancing growth hormone output by suppressing the growth hormone-inhibiting hormone
• Maintained activity even in the presence of elevated circulating growth hormone levels

Studies in rat models showed that hexarelin stimulates growth hormone secretion through mechanisms involving both direct pituitary action and hypothalamic pathways, with effects that persist longer than those of GHRH alone.

CD36 Scavenger Receptor Binding – Cardioprotection

A distinctive feature of hexarelin is its ability to bind and activate the CD36 scavenger receptor, a glycoprotein expressed at high levels in cardiac tissue. This non-GHSR pathway mediates many of hexarelin’s cardiovascular effects. Research has demonstrated:

• Direct cardioprotective actions independent of growth hormone elevation
• Protection against ischemia-reperfusion injury in heart tissue through CD36 activation
• Mitochondrial biogenesis promotion in adipocytes and cardiac cells
• Fat oxidation enhancement through CD36-mediated metabolic pathways

Photoaffinity labeling studies identified CD36 as a specific cardiac receptor for hexarelin, with binding affinity distinct from GHSR-1a, suggesting the existence of tissue-specific receptor populations.

Calcium Channel and PKC Modulation

Hexarelin influences intracellular calcium signaling and activates protein kinase C (PKC) pathways in cardiac tissue. Research in isolated cardiomyocytes has shown:

• Increased amplitude of intracellular calcium transients in ventricular myocytes
• Enhanced L-type calcium current, leading to positive inotropic effects
• PKC-dependent signaling mediating coronary vasoconstriction and contractility
• Concentration and time-dependent effects on papillary muscle contraction

These calcium-related mechanisms contribute to hexarelin’s acute cardiac effects and may play roles in both its protective and functional impacts on heart tissue.

HPA Axis Stimulation

Beyond growth hormone, hexarelin peptide stimulates the hypothalamic-pituitary-adrenal (HPA) axis, resulting in increased secretion of adrenocorticotropic hormone (ACTH), cortisol, and prolactin. Studies in humans revealed:

• Significant ACTH and cortisol release with peak levels occurring 30-45 minutes post-administration
• Arginine vasopressin (AVP) pathway involvement rather than CRH-mediated mechanisms
• Prolactin elevation through direct pituitary stimulation
• No effect on luteinizing hormone, follicle-stimulating hormone, or thyroid-stimulating hormone

The HPA axis activation occurs at lower doses than required for maximal growth hormone release, suggesting high receptor sensitivity in corticotroph cells.

PTEN/Akt Signaling Pathway

Recent investigations have identified hexarelin’s ability to modulate the PTEN/Akt signaling pathway, which plays critical roles in cell survival and cardiac remodeling:

• Downregulation of PTEN expression in cardiac tissue
• Enhanced Akt phosphorylation, promoting cell survival signals
• Reduced apoptosis in cardiomyocytes under stress conditions
• Prevention of pathological cardiac remodeling in heart failure models

This mechanism represents a novel therapeutic target for cardiac protection and may explain hexarelin’s sustained protective effects beyond acute administration.

Hexarelin Research Applications & Key Findings

Cardiovascular Research

Cardiac Ischemia and Myocardial Infarction

Hexarelin has been extensively studied in animal models of cardiac injury, demonstrating remarkable cardioprotective properties. Research in mouse and rat models of myocardial infarction has shown:

• Reduced infarct size by approximately 40-50% when administered within 30 minutes of coronary artery ligation
• Improved left ventricular ejection fraction maintained at 14 and 21 days post-infarction
• Enhanced cardiac cell survival through anti-apoptotic mechanisms mediated by CD36 activation
• Decreased levels of malondialdehyde and increased superoxide dismutase activity, indicating antioxidant effects

Studies revealed that a single oral dose of hexarelin administered at the acute phase after myocardial infarction protected chronic cardiac function, with effects including lower lung weight ratios (indicating reduced pulmonary congestion) and preserved contractility.

Cardiac Remodeling and Fibrosis

Research has demonstrated hexarelin’s ability to prevent pathological cardiac remodeling following injury:

• Significant reduction in interstitial collagen deposition in heart failure models
• Decreased left ventricular mass in treated animals compared to controls
• Improved diastolic function through reduction of cardiac stiffness
• Attenuated fibrosis in spontaneously hypertensive rats with chronic administration

Immunohistochemistry studies showed reduced expression of pro-fibrotic markers including transforming growth factor-beta and collagen type I in hexarelin-treated hearts.

Autonomic Nervous System Modulation

Hexarelin treatment influences autonomic balance, with beneficial effects on heart rate variability:

• Shift toward parasympathetic activity as evidenced by heart rate variability analysis
• Reduced plasma epinephrine and dopamine levels following myocardial infarction
• Lower sympathetic drive indicated by decreased low-to-high frequency power ratios
• Improved autonomic regulation potentially contributing to reduced arrhythmia risk

Metabolic and Body Composition Research

Lipid Metabolism and Dyslipidemia

Research in insulin-resistant and diabetic animal models has revealed hexarelin’s effects on lipid metabolism:

• Reduced plasma cholesterol concentrations in hypophysectomized and obese Zucker rats
• Improved lipid profiles including decreased triglycerides in metabolic syndrome models
• Enhanced fat oxidation through CD36-mediated mitochondrial biogenesis in white adipocytes
• Correction of dyslipidemia in non-obese insulin-resistant mice with twice-daily administration

Studies using mouse models demonstrated that hexarelin treatment improved metabolic parameters independent of significant changes in body weight or food intake.

Insulin Sensitivity and Glucose Homeostasis

Investigations in diabetic models have examined hexarelin’s metabolic effects:

• No adverse effects on glucose tolerance or insulin sensitivity in most models
• Preserved glucose homeostasis during chronic treatment in healthy subjects
• Potential protective effects on pancreatic beta-cell function in some studies
• Altered calcium and potassium processing in cardiac muscle of diabetic rats

Skeletal Muscle and Cachexia Research

Muscle Wasting Prevention

Studies in chemotherapy-induced cachexia models demonstrated hexarelin’s muscle-protective properties:

• Significant protection against cisplatin-induced muscle atrophy in rats
• Preserved mitochondrial function in skeletal muscle during toxic insults
• Maintained muscle fiber cross-sectional area compared to untreated controls
• Reduced inflammatory markers in muscle tissue during catabolic stress

Research comparing hexarelin to other growth hormone secretagogues showed comparable or superior efficacy in preventing muscle mass loss.

Neuroprotection Research

Neurodegenerative Disease Models

Emerging research has explored hexarelin’s neuroprotective potential:

• Increased neurogenesis in hippocampal regions in preclinical models
• Reduced neuroinflammation through modulation of microglial activation
• Enhanced cell survival in models of amyotrophic lateral sclerosis (ALS) using mutated neuroblastoma cells
• Protection against oxidative stress in brain tissue through antioxidant mechanisms

Studies in brain injury models showed hexarelin reduced lesion volumes and improved neurobehavioral outcomes compared to vehicle-treated controls.

Hexarelin Pharmacokinetics & Metabolism

Absorption & Distribution

Hexarelin exhibits favorable pharmacokinetic properties compared to many peptides, with research demonstrating activity via multiple administration routes. Following intravenous administration in animal models:

• Rapid distribution with detectable plasma levels within 5-10 minutes
• Volume of distribution of 387.7 ml/kg in dogs and 744 ml/kg in rats at steady state
• Systemic bioavailability of approximately 64% following subcutaneous administration in rats
• Oral bioavailability demonstrated in preclinical models, though significantly lower than parenteral routes

Studies using radiolabeled hexarelin showed highest tissue concentrations in the duodenum, kidney, and liver, with significant cardiac uptake corresponding to therapeutic effects.

Distribution studies revealed specific binding in cardiovascular tissues, with highest concentrations detected in ventricles, followed by atria, aorta, and coronary vessels, consistent with high CD36 receptor expression in these tissues.

Metabolism & Elimination

The metabolic pathways of hexarelin have been partially characterized in animal models:

• Plasma half-life of 75.9 minutes in rats and approximately 120 minutes in dogs following intravenous administration
• Systemic clearance of 7.6 ml/min/kg in rats and 4.28 ml/min/kg in dogs
• Growth hormone elimination half-life of approximately 55 minutes in human studies following hexarelin-induced release
• Peptidase degradation likely occurs, though specific enzymes have not been fully characterized

Research examining intestinal degradation identified deamidation at the lysine residue as a primary metabolic pathway, with trypsin-like enzymes implicated in the breakdown process.

Hepatic extraction studies in isolated perfused rat liver demonstrated significant first-pass metabolism, partially explaining the lower oral bioavailability compared to parenteral routes.

Excretion Pathways

Limited data on excretion routes indicates:

• Renal elimination appears to be the primary route for peptide fragments
• Biliary excretion contributes to clearance based on studies in bile duct-exteriorized rats
• No accumulation observed with repeated subcutaneous dosing across a 10-fold dose range
• Dose-independent clearance suggesting non-saturable elimination pathways

The discrepancy between relatively short plasma half-life and prolonged pharmacodynamic effects (growth hormone elevation persisting 3-4 hours) suggests either active metabolites, tissue retention, or persistent receptor activation beyond plasma clearance.

Hexarelin Research Protocols & Administration

Dosing in Published Research

Research investigations have employed diverse hexarelin doses depending on species, model, and administration route:

• Rat studies: 10-500 mcg/kg typical range, with 80-150 mcg/kg most common for twice-daily administration
• Mouse models: 0.3 mg/kg/day (300 mcg/kg) standard dose for cardiovascular protection studies
• Dog studies: 1-100 mcg/kg used in pharmacokinetic and pharmacodynamic investigations
• Human studies: 0.5-2 mcg/kg intravenous bolus; 20-60 mcg/kg intranasal administration (3 times daily in pediatric growth studies)

Important: These are experimental doses used in animal and early human research studies and cannot be extrapolated to other species due to significant differences in metabolism, receptor density, pharmacokinetics, and peptide degradation rates across species. Hexarelin exhibits species-specific pharmacological profiles that profoundly influence both efficacy and safety parameters.

Administration Routes in Research

Multiple delivery methods have been investigated in preclinical and clinical studies:

• Intravenous injection – Used in acute pharmacodynamic studies in both animals and humans; produces rapid, high-amplitude growth hormone peaks
• Subcutaneous injection – Most common route in chronic animal studies; bioavailability of 64% in rats; sustained absorption profile
• Intraperitoneal injection – Frequently used in rodent research; reliable systemic delivery with rapid absorption
• Oral administration – Unusual for peptides; hexarelin demonstrates measurable oral activity though with low bioavailability (0.3% in humans based on GH response)
• Intranasal administration – Evaluated in pediatric studies; equivalent efficacy to intravenous dosing at 20-fold higher doses
• Intracerebroventricular – Used in mechanistic studies to distinguish central versus peripheral effects

Common Model Organisms

Hexarelin has been studied across multiple species and experimental systems:

• Rats – Primary research model (Sprague-Dawley, Wistar, obese Zucker strains); extensive cardiovascular and metabolic data
• Mice – C57BL/6J strain commonly used; myocardial infarction, metabolic syndrome, and genetic knockout models
• Dogs – Employed for pharmacokinetic characterization and cardiovascular assessments
• Rabbits – Historical studies in growth hormone release mechanisms
• Humans – Limited to acute pharmacodynamic studies in healthy volunteers and small pediatric growth hormone deficiency trials
• Cell culture – H9c2 cardiac myocytes, primary rat cardiomyocytes, endothelial cells, adipocytes, and neuroblastoma cell lines

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite over 30 years of preclinical research, hexarelin faces substantial translational barriers that limit its research utility and prevent clinical development.

Lack of Human Clinical Data

The most significant limitation is the near-complete absence of therapeutic human trials:

• No completed Phase II or III clinical trials for any therapeutic indication in peer-reviewed literature
• Limited Phase I data restricted to acute pharmacodynamic assessments in healthy volunteers
• Pediatric growth studies initiated but never published as completed therapeutic trials
• Human safety profile incompletely characterized beyond acute single-dose studies
• Long-term human safety completely unstudied
• Optimal therapeutic dosing in humans undetermined
• Chronic desensitization observed in animal studies with repeated dosing (50-75% efficacy reduction over weeks)

This absence of clinical data represents a critical gap given the extensive preclinical evidence for cardiovascular and metabolic benefits.

Mechanistic Understanding Gaps

Fundamental aspects of hexarelin’s mechanism remain incompletely understood:

• Relative contribution of GHSR-1a versus CD36 pathways to different effects unclear
• Tissue-specific receptor populations require further characterization
• Active metabolites versus parent compound contribution to prolonged effects unknown
• Receptor desensitization mechanisms incompletely elucidated despite observed tolerance
• Species differences in receptor expression and signaling not fully mapped

The lack of GHSR-1a expression in some cell types that respond to hexarelin suggests additional unidentified receptors may exist.

Long-Term Safety Considerations

Critical safety questions remain unanswered:

• Chronic cardiovascular effects beyond 3-4 weeks unstudied even in animals
• Oncogenic potential inadequately assessed despite effects on cell proliferation pathways
• Endocrine disruption with prolonged HPA axis stimulation not evaluated long-term
• Receptor downregulation consequences with extended use unknown
• Drug interaction potential with cardiovascular medications uncharacterized
• Reproductive and developmental toxicity inadequately studied
• Rebound effects after treatment cessation not systematically evaluated

The partial desensitization observed in chronic studies raises questions about sustained therapeutic benefit.

Regulatory & Competitive Sport Status

FDA Position

Hexarelin has not received FDA approval for any indication:

• Not approved for human or veterinary therapeutic use in the United States
• Not recognized as GRAS (Generally Recognized as Safe)
• Classification as research chemical only, not for human consumption
• No established medical use basis for therapeutic applications
• Development apparently discontinued by pharmaceutical companies for clinical use

The FDA has not issued specific warning letters regarding hexarelin to the same extent as some other research peptides, but its unapproved status means it cannot be legally marketed for human use.

WADA Prohibition

The World Anti-Doping Agency classifies hexarelin (examorelin) as a prohibited substance:

• Listed under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics)
• Specifically named among prohibited GH-releasing peptides (GHRPs) including examorelin, GHRP-1, GHRP-2, and GHRP-6
• Prohibited at all times (both in-competition and out-of-competition)
• No Therapeutic Use Exemptions (TUEs) available due to lack of approved therapeutic use
• Detection methods available for anti-doping testing programs

WADA’s prohibition reflects hexarelin’s classification as a growth hormone secretagogue with performance-enhancing potential.

Research Classification: Hexarelin is available only for laboratory research use. It is not intended for human consumption, medical use, or veterinary applications. All research must be conducted under appropriate ethical oversight and regulatory compliance with institutional review board approval where applicable.

References

1. Deghenghi, R., Cananzi, M.M., Torsello, A., Battisti, C., Müller, E.E., & Locatelli, V. (1994). GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sciences, 54(18), 1321-1328. PubMed
   
2. Imbimbo, B.P., Mant, T., Edwards, M., Amin, D., Dalton, N., Boutignon, F., Lenaerts, V., Wüthrich, P., & Deghenghi, R. (1994). Growth hormone-releasing activity of hexarelin in humans. A dose-response study. European Journal of Clinical Pharmacology, 46(5), 421-425. PubMed
   
3. Massoud, A.F., Hindmarsh, P.C., & Brook, C.G. (1996). Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study. Journal of Clinical Endocrinology and Metabolism, 81(12), 4338-4341. PubMed
   
4. Korbonits, M., Kaltsas, G., Perry, L.A., Putignano, P., Grossman, A.B., Besser, G.M., & Trainer, P.J. (1999). The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. Journal of Clinical Endocrinology and Metabolism, 84(7), 2489-2495. PubMed
   
5. Rahim, A., O’Neill, P.A., & Shalet, S.M. (1998). Growth hormone status during long-term hexarelin therapy. Journal of Clinical Endocrinology and Metabolism, 83(5), 1644-1649. PubMed
   
6. Mao, Y., Tokudome, T., & Kishimoto, I. (2014). The cardiovascular action of hexarelin. Journal of Geriatric Cardiology, 11(3), 253-258. PubMed
   
7. Bodart, V., Febbraio, M., Demers, A., McNicoll, N., Pohankova, P., Perreault, A., Sejlitz, T., Escher, E., Silverstein, R.L., Lamontagne, D., & Ong, H. (2002). CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circulation Research, 90(7), 844-849. PubMed
   
8. McDonald, H., Peart, J., Kurniawan, N., Galloway, G., Royce, S., Samuel, C.S., & Chen, C. (2018). Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction. Physiological Reports, 6(9), e13699. PubMed
   
9. Mao, Y., Tokudome, T., Otani, K., Kishimoto, I., Nakanishi, M., Hosoda, H., Miyazato, M., & Kangawa, K. (2014). One dose of oral hexarelin protects chronic cardiac function after myocardial infarction. Hormone and Metabolic Research, 46(6), 406-416. PubMed
   
10. Agbo, E., Liu, D., Li, M., Saahene, R.O., Chen, L., Zhao, L., Wang, Y., & Tian, G. (2019). Modulation of PTEN by hexarelin attenuates coronary artery ligation-induced heart failure in rats. Turkish Journal of Medical Sciences, 49(3), 945-958. PubMed
    
11. Xu, X., Pang, J., Yin, H., Li, M., Hao, W., Chen, C., & Cao, J.M. (2012). Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat. American Journal of Physiology – Heart and Circulatory Physiology, 303(6), H703-711. PubMed
    
12. Rossoni, G., Locatelli, V., Schweiger, F., Torsello, A., De Gennaro Colonna, V., Bernareggi, M., Deghenghi, R., Müller, E.E., & Berti, F. (1998). Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology, 140(9), 4024-4031. PubMed
    
13. Rodrigue-Way, A., Demers, A., Ong, H., & Tremblay, A. (2007). A growth hormone-releasing peptide promotes mitochondrial biogenesis and a fat burning-like phenotype through scavenger receptor CD36 in white adipocytes. Endocrinology, 148(3), 1009-1018. PubMed
    
14. Chen, C., Wu, R., Zhao, Y., Tian, Y., Guo, Y., Wang, S., Xu, C., Liu, X., Wang, S., & Xu, H. (2017). Hexarelin, a growth hormone secretagogue, improves lipid metabolic aberrations in nonobese insulin-resistant male MKR mice. Endocrinology, 158(10), 3174-3187. PubMed
    
15. Torsello, A., Bresciani, E., Rossoni, G., Avallone, R., Tulipano, G., Cocchi, D., Bulgarelli, I., Deghenghi, R., Berti, F., & Locatelli, V. (2003). Ghrelin plays a minor role in the physiological control of cardiac function in the rat. Endocrinology, 144(5), 1787-1792. PubMed
    
16. Bedendi, I., Alloatti, G., Marcantoni, A., Malan, D., Catapano, F., Ghè, C., Deghenghi, R., Ghigo, E., & Muccioli, G. (2003). Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin. European Journal of Pharmacology, 476(1-2), 87-95. PubMed
    
17. Meanti, R., Rizzi, L., Bresciani, E., Molteni, L., Locatelli, V., & Torsello, A. (2023). Hexarelin modulation of MAPK and PI3K/Akt pathways in Neuro-2A cells inhibits hydrogen peroxide-induced apoptotic toxicity. International Journal of Molecular Sciences, 24(3), 2862. PubMed
    
18. Conley, L.K., Teik, J.A., Deghenghi, R., Imbimbo, B.P., Giustina, A., Locatelli, V., & Wehrenberg, W.B. (1995). Mechanism of action of hexarelin and GHRP-6: analysis of the involvement of GHRH and somatostatin in the rat. Neuroendocrinology, 61(1), 44-50. PubMed
    
19. Tivesten, A., Bollano, E., Caidahl, K., Kujacic, V., Sun, X.Y., Hedner, T., Hjalmarson, A., Bengtsson, B.A., & Isgaard, J. (2000). The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology, 141(1), 60-66. PubMed
    
20. Pang, J.J., Xu, R.K., Xu, X.B., Cao, J.M., Ni, C., Zhu, W.L., Asotra, K., Chen, M.C., & Chen, C. (2004). Hexarelin protects rat cardiomyocytes from angiotensin II-induced apoptosis in vitro. American Journal of Physiology – Heart and Circulatory Physiology, 286(3), H1063-1069. PubMed
    
21. Westberg, C., Holmqvist, M., Roumi, M., Melin, I., Deghenghi, R., Wütrich, P., & Ong, H. (2001). Hexarelin – evaluation of factors influencing oral bioavailability and ways to improve absorption. Journal of Pharmacy and Pharmacology, 53(9), 1257-1264. PubMed
    
22. Boghen, M.F., Meyers, C.A., Imbimbo, B.P., Cockle, S.M., Mant, T., Edwards, M., & Deghenghi, R. (1995). Radioimmunoassay for hexarelin, a peptidic growth hormone secretagogue, and its pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis, 13(10), 1275-1280. PubMed
    
23. Mao, Y., Tokudome, T., Otani, K., Kishimoto, I., Miyazato, M., & Kangawa, K. (2013). Hexarelin treatment in male ghrelin knockout mice after myocardial infarction. Endocrinology, 154(10), 3847-3854. PubMed
    
24. Locatelli, V., Rossoni, G., Schweiger, F., Torsello, A., De Gennaro Colonna, V., Bernareggi, M., Deghenghi, R., Müller, E.E., & Berti, F. (1999). Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology, 140(9), 4024-4031. PubMed
    
25. Deghenghi, R. (2008). Hexarelin: A multi-receptor peptide. Journal of Endocrinological Investigation, 31(7), 680. Article Link
    

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. Hexarelin is intended for laboratory research use only.